ATC code of the medicinal product
(WHO classification) |
Active substance |
Reimbursement condition |
|
B03BA01
B03BA02
B03BA03 |
cyanocobalamin
cyanocobalamin tannin complex
hydroxocobalamin |
Pernicious anaemia
Vitamin B12 deficiency caused by an operation of the digestive tract or "Sprue" |
|
C08CA03
C08CA05
C08CA08
C08CA09
C08CA13
C09BB02 |
isradipine
nifedipine
nitrendipine
lacidipine
lercanidipine
enalaprile and lercanidipine |
Patients with hypertension or any other type of cardiovascular disease requiring treatment where treatment with dihydropyridine calcium channel blockers eligible for general unconditional reimbursement is not tolerated, or in exceptional cases has been deemed inappropriate by a doctor based on an overall clinical assessment of the patient's condition. |
|
C09CA01
C09CA02
C09CA03
C09CA04
C09CA06
C09CA07
C09CA08
C09DA01
C09DA02
C09DA03
C09DA04
C09DA06
C09DA07
C09DA08
C09DB01
C09XA02
C09XA52 |
losartan
eprosartan
valsartan
irbesartan
candesartan
telmisartan
olmesartan
losartan + HCT
eprosartan + HCT
valsartan + HCT
irbesartan + HCT
candesartan + HCT
telmisartan + HCT
olmesartan + HCT
valsartan + amlodipine
aliskiren
aliskiren + HCT |
Patients with hypertension or any other type of cardiovascular disease requiring treatment, where treatment with medicinal products acting on the renin-angiotensin system that are eligible for general unconditional reimbursement has proven inadequate or is not tolerated, or in exceptional cases has been deemed inappropriate by a doctor based on an overall clinical assessment of the patient's condition. |
|
C10AA04
C10AA05
C10AA07
C10AC01
C10AC02
C10AD06
C10AD52
C10AX09
C10BA02 |
fluvastatin
atorvastatin
rosuvastatin
colestyramine
colestipol
acipimox
nicotine acid, combinations
ezetimibe
ezetimibe and simvastatin in combination |
Patients with hyperlipidemia requiring treatment who have not responded adequately to or who are intolerant to statins that are eligible for general reimbursement. |
|
C10AB04 |
gemfibrozil |
Patients with isolated, severely elevated triglycerides or patients with combined hyperlipidemia possibly combined with statins. |
|
J07AL01 |
pneumococcus, purified polysaccharides antigen |
Persons with
performed/planned splenectomy, organ transplantation, cochlear implantation,
a dysfunctional spleen,
Cerobrospinal fluid leakage
previous invasive pneumococcal disease
Immunosuppression (e.g. induced by HIV infection or associated with lymphoma)
In addition, persons under the age of 18 with
- cyanotic heart disease
- congestive heart failure
- palliative surgery of heart disease
- hemodynamically significant residual after heart surgery
- chronic lung disease (e.g. cystic fibrosis)
- hypodynamic respiratory insufficiency
- nephrotic syndrome
- immunodeficiencies, excl. agammaglobulinaemia and SCID
|
|
J07BC01 |
hepatitis B, purified antigen |
- persons with Down's syndrome
- persons who have sustained pertinent needle stick injuries
|
|
M03BX02 |
tizanidine |
Chronic spasticity caused by central nervous system disorders |
|
N03AA02
N03AE01 |
phenobarbital
clonazepam |
Chronic spasticity caused by central nervous system disorders
Epilepsy |
|
N03AX12 |
gabapentin |
Epilepsy |
|
N03AX16 |
pregabalin |
Epilepsy
Generalised anxiety disorder |
|
N04BC09 |
rotigotine# |
Parkinson's disease |
|
N04BD02 |
rasagiline |
Parkinson patients who have not responded adequately to or who are intolerant to selegiline. |
|
N06AX21 |
duloxetine* |
Moderate to severe depression and/or generalised anxiety disorder |
